Navigation Links
ALS Therapy Development Institute Receives $1.6 Million Grant From the Department of Defense for Lou Gehrig's Disease Research
Date:1/12/2010

ALS (Lou Gehrig's disease) named Service Related Disorder Earlier Last Year

CAMBRIDGE, Mass., Jan. 12 /PRNewswire-USNewswire/ -- In recognition of multiple studies connecting ALS to military service, the 2010 Defense Appropriations Act, signed by President Obama on December 22, 2009, provided for the grant of $1.6 million for research and development of potential therapeutics for Amyotrophic Lateral Sclerosis (ALS, Lou Gehrig's disease).  Deemed a "service-related disorder" by the Veterans Administration (VA) in July of 2008, ALS affects approximately 30,000 Americans at any given time.  With no robust therapeutics currently available, those afflicted survive on average only 36 months from diagnosis.  The funding approved will be sent to the ALS Therapy Development Institute (ALS TDI), a non-profit, independent research center devoted to the development of therapeutics that slow and stop progression of the fatal neurodegenerative disease.

"This grant from the [Department of Defense], bringing their total spent on ALS research at our Institute alone to nearly $5.5 million over a period of five years, shows their commitment to our veterans.  It is unacceptable that those stricken by the disease, for whatever reason, including our servicemen and servicewomen returning from war, do not have therapeutic options available.  We must move faster toward providing truly efficacious interventions for all those living with ALS today," said Steve Perrin, Ph.D., chief executive officer and chief scientific officer at ALS TDI.

The request for spending was sponsored by Congressman Michael Capuano (D-MA).  "Congressman Capuano and his staff recognize the need to get out ahead of this issue.  They have been champions for those veterans who have sacrificed for our country, only to come home to face this horrible disease.  We are grateful and mindful of the fact that they believe in ALS TDI's ability to discover and develop treatments for veterans and all those facing ALS," said Carol Hamilton, director of government affairs for ALS TDI.

Through a multi-year contract with the DOD, ALS TDI will use the funding to advance promising therapies for ALS through its rigorous preclinical screen model.  The preclinical drug discovery and development program at ALS TDI is made up of several stages, including both in vitro and in vivo screening platforms.  This funding will have a direct impact on the Institute's ability to identify, validate and advance several, potential therapeutics toward the clinic.  Currently, the Institute has 30 projects in its active drug development pipeline, including small molecules, gene therapeutic and biologics. The Institute provides updates on its research efforts directly to the ALS community through a variety of mechanisms, including a quarterly research webcast, the next of which will be held on January 14, 2010.

"This grant is designed to move with the same sense of urgency felt by those living with ALS today, and their families.  This direct appropriation to ALS TDI will cut down on the time it takes to get money into the lab by avoiding many of the traditional bureaucratic obstacles, all the while ensuring strict oversight of how this money is spent.  It is these types of investments that will ultimately get the job done for our veterans and all others facing ALS today.  This is about turning hope into work, and we are grateful for the opportunity to follow-through on that charge," continued Dr. Perrin.

Of note, as well, is the support of other members of Congress.  The late Senator Edward Kennedy provided a long-term commitment to ALS TDI, and Senator Lisa Murkowski (R-AL), of The Senate Appropriations Committee, and Congressman Henry Brown (R-SC), Ranking Member of the House VA Subcommittee on Health have both been very helpful in their commitment to addressing the needs of veterans, and all citizens living with ALS.  The Institute would also like to recognize Brigadier General Tom Mikolajcik, USAF (Ret.), who was diagnosed with ALS in 2005, for his relentless efforts on behalf of military veterans.

About ALS TDI

The mission of the ALS Therapy Development Institute (ALS TDI) is to develop effective therapeutics that slow or stop amyotrophic lateral sclerosis (ALS, Lou Gehrig's disease), as soon as possible.  Focused on meeting this urgent unmet medical need, ALS TDI executes a robust discovery program, while running the world's largest efforts to pre-clinically validate potential therapeutics; including small molecules, protein biologics, gene therapies and cell-based constructs.  The world's first non-profit biotech, ALS TDI has developed an industrial-scale platform that allows for the development and testing of dozens of potential therapeutics each year.  Built by and for patients, the Institute is the world's only non-profit biotechnology company with more than 30 professional scientists. In addition, the Cambridge, Massachusetts based research Institute collaborates with leaders in both academia and industry.  For more information, please visit us online at www.als.net.

Media Contact: Robert Goldstein, ALS TDI, 617-441-7295, rgoldstein@als.net

SOURCE ALS Therapy Development Institute

RELATED LINKS
http://www.als.net

'/>"/>

SOURCE ALS Therapy Development Institute
Copyright©2010 PR Newswire.
All rights reserved

Related medicine news :

1. MBM ScienceBridge GmbH Negotiates License Agreement Between the Georg-August-University Gottingen, Universitatsmedizin, the University of Regensburg, and the UKs Medical Research Council Technology for a New Therapy of Inflammatory and Immune Disea
2. New hope for therapy in heartburn-related cancer
3. Breast cancer multigene test helping patients avoid chemotherapy
4. Psychotherapy May Help Teen Girls Avoid Obesity
5. After Cochlear Implant, Music Therapy May Aid Speech
6. High antiretroviral therapy adherence associated with lower health care costs
7. Music therapy can assist toddlers communication rehabilitation process
8. UV LED therapy shows promising results in preventing focal seizures
9. Sexual function does not continuously decline after radiation therapy treatments for prostate cancer
10. Ring in a Healthy New Year with Massage Therapy in 2010
11. Lithium Beats Valproate for Long-Term Bipolar Therapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... ... June 26, 2016 , ... On June 10-11, 2016, A ... 2016 Cereal Festival and World’s Longest Breakfast Table in Battle Creek, MI, where the ... history as home to some of the world’s leading providers of cereal and other ...
(Date:6/25/2016)... D.C. (PRWEB) , ... June 25, 2016 , ... ... discuss health policy issues and applications at AcademyHealth’s Annual Research Meeting June 26-28, ... their work on several important health care topics including advance care planning, healthcare ...
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern ... Laude and his M.D from the David Geffen School of Medicine at UCLA. He ... Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program ...
(Date:6/24/2016)... ... June 24, 2016 , ... Those who have experienced traumatic events may ... to unhealthy avenues, such as drug or alcohol abuse, as a coping mechanism. To ... for healthy coping following a traumatic event. , Trauma sufferers tend to feel a ...
(Date:6/24/2016)... ... June 24, 2016 , ... Dr. ... accelerated orthodontic treatment. Dr. Cheng has extensive experience with all areas of orthodontics, ... and accelerated osteogenic orthodontics. , Micro-osteoperforation is a revolutionary adjunct to orthodontic ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... June 23, 2016 Research and Markets ... Medical Market Analysis 2016 - Forecast to 2022" report ... The report contains up to date financial data derived from ... of major trends with potential impact on the market during ... market segmentation which comprises of sub markets, regional and country ...
(Date:6/23/2016)... June 23, 2016 Bracket , a leading ... next generation clinical outcomes platform, Bracket eCOA (SM) 6.0, ... June 26 – 30, 2016 in Philadelphia ... Clinical Outcome Assessment product of its kind to fully integrate ... Bracket eCOA 6.0 is a flexible platform for electronic ...
(Date:6/23/2016)... -- Astellas today announced the establishment of Astellas Farma Colombia (AFC), a new affiliate with operations headquartered in ... . ... ... ... Astellas is ...
Breaking Medicine Technology: